Omnicell reported its third‑quarter 2025 financial results, with total revenue of $311 million, a 10% year‑over‑year increase from $282 million in Q3 2024. GAAP net income was $5 million, down from $9 million, while non‑GAAP net income was $24 million, a decline from $26 million. Non‑GAAP EBITDA rose to $41 million, up from $39 million, and the company’s non‑GAAP gross margin was 44.2%, slightly lower than 44.5% in the prior year.
The company raised its full‑year 2025 guidance. Q4 revenue is now projected at $306 million to $316 million, and total revenue for the year is $1.177 billion to $1.187 billion. Product revenue guidance is $661 million to $666 million, and service revenue guidance is $131 million to $136 million. Full‑year non‑GAAP EBITDA is expected to be $140 million to $146 million, with earnings per share between $1.63 and $1.73.
Omnicell highlighted several operational milestones. It repaid $175 million of convertible senior notes that matured on September 15 2025, repurchased 1.99 million shares for $62 million under a $75 million repurchase program approved in May 2025, and maintained cash and cash equivalents of $180 million against debt of $167 million.
Management noted that demand for its XT Series automated dispensing systems and technical services remained robust, while tariff headwinds of approximately $6 million continued to weigh on profitability. The company’s gross margin was 44.2% in Q3, slightly lower than 44.5% in Q3 2024.
The company also introduced new chief financial officer Baird Radford and emphasized its transformation into an intelligent medication management technology company, with the OmniSphere cloud‑based platform positioned to drive recurring revenue growth.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.